Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

Abstract

BACKGROUND:

Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs.

METHODS:

Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m(2), q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1).

RESULTS:

Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7 %) and as at least third-line therapy in a further 3 (27.3 %). The best RECIST response was a partial response (PR) in one patient (9.1 %) and stable disease (SD) in eight patients (72.7 %). Disease-control rate (DCR = PR + SD) was 81.8 %. After a median follow-up of 29.2 months, the median PFS was 11.6 months (95 % CI = 2.0; 15.2 months) and the median OS was 22.3 months (95 % CI = 9.1 months; not reached). The median GMI was 1.49 (range: 0.11-4.12).

CONCLUSION:

Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.

• Authors: J Khalifa, M Ouali, L Chaltiel, S Le Guellec, A Le Cesne, J-Y Blay, P Cousin, L Chaigneau, E Bompas, S Piperno-Neumann, B Bui-Nguyen, M Rios, J-P Delord, N Penel, C Chevreau
• Journal: BMC cancer (BMC Cancer) Vol. 15 Pg. 700 (Oct 15 2015) ISSN: 1471-2407 [Electronic] England
• PMID: 26472661 (Publication Type: Journal Article)

Chemical References

• Dioxoles
• Tetrahydroisoquinolines
• Trabectedin

Topics

• Adult
• Dioxoles (administration & dosage)
• Disease-Free Survival
• Female
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neoplasm Staging
• Prognosis
• Retrospective Studies
• Sarcoma (drug therapy, pathology)
• Solitary Fibrous Tumors (drug therapy, pathology)
• Tetrahydroisoquinolines (administration & dosage)
• Trabectedin
• Treatment Outcome